/Johnson%20%26%20Johnson%20corporate%20building%20By%20PixelBiss.jpeg){kind=tracking}
Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
/Gilead%20sign%20is%20seen%20during%20the%20fifth%20China%20International%20Import%20Expo%20By%20Eagle.jpeg)
Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.
The high-momentum groups leading us to the upside, like tech and chips, are now withering...while the less-popular, less-exciting names, like consumer staples and health care, are shining.
/Bristol%20Myers%20Squibb%20logo%20under%20a%20magnifying%20glass_%20By%20Casimiro.jpeg)
Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
/CVS%20Health%20Corp%20corporate%20office-by%20JHVEPhoto%20via%20iStock.jpg)
CVS Health has rallied the broader market over the past year, and analysts remain highly optimistic about the stock’s prospects.
/Agilent%20Technologies%20Inc_%20HQ%20sign-by%20hapabapa%20via%20iStock.jpg)
Agilent Technologies is poised to release its third-quarter results soon, and analysts are projecting a single-digit earnings rise.
Veeva Systems is scheduled to post its second-quarter results soon, and analysts project a double-digit earnings growth.
The Cooper Companies is set to report Q3 earnings, with analysts expecting a marginal year-over-year EPS growth.
/Medtronic%20sign%20seen%20at%20its%20Irvine%20office_By%20Tada%20Images.jpeg)
: Medtronic is set to report Q1 earnings, with analysts expecting high single-digit year-over-year EPS growth.
/Regeneron%20Pharmaceuticals%20logo%20is%20seen%20on%20a%20screen%20and%20a%20hand%20holding%20pills_%20By%20Rafael%20Henrique.jpeg)
Regeneron Pharmaceuticals is set to report its second-quarter results this month, with analysts expecting a double-digit decline in earnings year over year.